Skip to main content
Journal cover image

The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.

Publication ,  Journal Article
Herold, CI; Blackwell, KL
Published in: Breast
January 2008

The primary goal of systemic adjuvant therapy for breast cancer is to control the risk of recurrence following surgery, thereby improving long-term survival. For many years, tamoxifen has served as the standard adjuvant endocrine therapy for postmenopausal women with hormone-sensitive breast cancer. The entry of the third-generation aromatase inhibitors (AIs) exemestane, anastrozole and letrozole as adjuvant therapy has introduced several different treatment options. Indirect comparisons suggest that appreciable differences may exist between the AIs in terms of early risk reduction, especially the risk for early distant metastases. Possible differences in efficacy may be related to differences in potency. Two ongoing trials directly comparing two AIs - the Femara versus Anastrozole Clinical Evaluation and MA.27 - may provide further information.

Duke Scholars

Published In

Breast

DOI

ISSN

0960-9776

Publication Date

January 2008

Volume

17 Suppl 1

Start / End Page

S15 / S24

Location

Netherlands

Related Subject Headings

  • Triazoles
  • Treatment Outcome
  • Tamoxifen
  • Randomized Controlled Trials as Topic
  • Quality of Life
  • Oncology & Carcinogenesis
  • Nitriles
  • Neoplasm Staging
  • Neoplasm Metastasis
  • Letrozole
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Herold, C. I., & Blackwell, K. L. (2008). The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. Breast, 17 Suppl 1, S15–S24. https://doi.org/10.1016/S0960-9776(08)70004-3
Herold, Christina I., and Kimberly L. Blackwell. “The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.Breast 17 Suppl 1 (January 2008): S15–24. https://doi.org/10.1016/S0960-9776(08)70004-3.
Herold, Christina I., and Kimberly L. Blackwell. “The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.Breast, vol. 17 Suppl 1, Jan. 2008, pp. S15–24. Pubmed, doi:10.1016/S0960-9776(08)70004-3.
Journal cover image

Published In

Breast

DOI

ISSN

0960-9776

Publication Date

January 2008

Volume

17 Suppl 1

Start / End Page

S15 / S24

Location

Netherlands

Related Subject Headings

  • Triazoles
  • Treatment Outcome
  • Tamoxifen
  • Randomized Controlled Trials as Topic
  • Quality of Life
  • Oncology & Carcinogenesis
  • Nitriles
  • Neoplasm Staging
  • Neoplasm Metastasis
  • Letrozole